Loading clinical trials...
Loading clinical trials...
A Multicenter, Randomized, Placebo-controlled, Double-blind, 26 Week Study to Evaluate the Efficacy and Safety of Amantadine HCl Extended Release Tablets in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesias
Conditions
Interventions
amantadine HCl ER
Placebo
Locations
56
United States
Tucson, Arizona, United States
Fountain Valley, California, United States
Irvine, California, United States
Pasadena, California, United States
Ventura, California, United States
Boulder, Colorado, United States
Start Date
July 30, 2014
Primary Completion Date
May 20, 2016
Completion Date
May 20, 2016
Last Updated
February 16, 2022
NCT07330258
NCT06508801
NCT07384429
NCT02119611
NCT07310264
NCT07216976
Lead Sponsor
Adamas Pharmaceuticals, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions